Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Akebia Therapeutics, Inc. (AKBA) had Revenue of $160.18M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$160.18M
Net Income	$-69.41M
Cost of Goods Sold	$63.18M
Gross Profit	$97.00M
Operating Expenses	$210.65M
Operating Income	$-50.47M
Non-Operating Income/Expense	$-18.94M
Pre-Tax Income	$-69.41M
Normalized Pre-Tax Income	$-69.41M
Income after Taxes	$-69.41M
Income from Continuous Operations	$-69.41M
Consolidated Net Income/Loss	$-69.41M
Normalized Income after Taxes	$-69.41M
EBIT	$-50.47M
EBITDA	$-8.77M
Weighted-Average Shares Outstanding (Basic)	210.95M
Weighted-Average Shares Outstanding (Diluted)	210.95M
Earnings per Share (EPS) (Basic)	$-0.33
Earnings per Share (EPS) (Diluted)	$-0.33
Balance Sheet Financials
Current Assets	$113.83M
Property, Plant, and Equipment	$2.20M
Long-Term Assets	$106.84M
Total Assets	$220.67M
Current Liabilities	$80.91M
Long-Term Debt	$38.69M
Long-Term Liabilities	$188.94M
Total Liabilities	$269.86M
Common Equity	$-49.19M
Tangible Shareholders Equity	$-108.23M
Shareholders Equity	$-49.19M
Common Shares Outstanding	224.85M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-40.66M
Cash Flow from Investing Activities	$-0.03M
Cash Flow from Financial Activities	$49.66M
Beginning Cash	$44.58M
End Cash	$53.55M
Increase/Decrease in Cash	$8.97M
Stock-Based Compensation	$7.78M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.41
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-3.69
Debt to Equity Ratio	-0.79
Gross Margin	60.56%
Operating Margin	-31.51%
EBIT Margin	-31.51%
EBITDA Margin	-5.48%
Pre-Tax Profit Margin	-43.33%
Profit Margin	-43.33%
Free Cash Flow	$-40.69M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.73
Inventory Turnover	3.89
Receiveable Turnover	4.66
Days Sales in Receivables	78.31
Return on Equity	141.12%
Return on Tangible Equity	64.13%
Return on Assets	-31.45%
Return on Investments	661.55%
Book Value Per Share	$-0.22
Free Cash Flow per Share	$-0.19
Operating Cash Flow per Share	$-0.19

Data from Zacks Investment Research, Inc.